Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Blog Article

Editorial summary Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed Used Goal Skates DNA repair, but drug resistance remains a clinical hurdle.Recent advances in the identification of VESTS SUIT PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.